SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
DCTH reported Third Quarter 2026 results. The price and volatility reaction is pending.
DCTHearnings

Delcath Systems, Inc. (DCTH) Q3 FY2026 earnings

November 9, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $35.1 million for the third quarter of 2026, compared to $20.6 million in the third quarter of 2025.
  • HEPZATO KIT revenue was $32.7 million for the third quarter of 2026, compared to $19.3 million in the third quarter of 2025.
  • Net income was $7.0 million for the third quarter of 2026, compared to $0.8 million in the third quarter of 2025.
  • Non-GAAP adjusted EBITDA was $11.5 million for the third quarter of 2026, compared to $5.3 million in the third quarter of 2025.
  • Gross margins were 89% for the third quarter of 2026, compared to 87% in the third quarter of 2025.
  • Cash provided by operations was $8.2 million for the third quarter of 2026, compared to $4.8 million in the third quarter of 2025.

Guidance

  • Fiscal year 2026 total HEPZATO KIT and CHEMOSAT revenue is expected to range from $115 million to $117 million.
  • Full year 2026 gross margins are expected to be in the range of 87% to 89%.
  • The company expects positive adjusted EBITDA for fiscal year 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →